Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CCM2 antibody (N-Term)

This anti-CCM2 antibody is a Rabbit Polyclonal antibody detecting CCM2 in WB and IF. Suitable for Human.
Catalog No. ABIN616006

Quick Overview for CCM2 antibody (N-Term) (ABIN616006)

Target

See all CCM2 Antibodies
CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Reactivity

  • 25
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Human

Host

  • 17
  • 7
  • 1
Rabbit

Clonality

  • 21
  • 4
Polyclonal

Conjugate

  • 18
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This CCM2 antibody is un-conjugated

Application

  • 16
  • 5
  • 5
  • 4
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), Immunofluorescence (IF)
  • Binding Specificity

    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    AA 1-444, N-Term

    Specificity

    This antibody detects recombinant Human CCM-2 in Western Blot and native CCM-2 in Immunohistochemistry.

    Cross-Reactivity (Details)

    Species reactivity (tested):Human.

    Purification

    Protein A Chromatography

    Immunogen

    Highly pure (> 95%) recombinant Human CCM-2 (Cerebral cavernous malformations 2 protein, aa: Met1-Ala444) from E.coli.
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Reconstitution

    Restore in sterile water to a concentration of 0.1-1.0 mg/mL.

    Buffer

    5 mM PBS pH 7.2 without preservatives

    Preservative

    Without preservative

    Handling Advice

    Avoid repeated freezing and thawing.

    Storage

    4 °C/-20 °C

    Storage Comment

    Prior to reconstitution store at 2-8 °C for one month or dessicated at -20 °C for longer. Following reconstitution store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
  • Target

    CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

    Alternative Name

    Malcavernin

    Background

    Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Familial CCM is caused by mutations in KRIT1 (CCM1) or in malcavernin (CCM2). The roles of the CCM proteins in the pathogenesis of the disorder remain largely unknown. It was shown that the CCM1 gene product, KRIT1, interacts with the CCM2 gene product, malcavernin. Analogous to the established interactions of CCM1 and beta1 integrin with ICAP1, the CCM1/CCM2 association is dependent upon the phosphotyrosine binding (PTB) domain of CCM2. A familial CCM2 missense mutation abrogates the CCM1/CCM2 interaction, suggesting that loss of this interaction may be critical in CCM pathogenesis. CCM2 and ICAP1 bound to CCM1 via their respective PTB domains differentially influence the subcellular localization of CCM1. The data indicate that the genetic heterogeneity observed in familial CCM may reflect mutation of different molecular members of a coordinated signaling complex.Synonyms: C7orf22, CCM2, Cerebral cavernous malformations 2 protein, PP10187

    Gene ID

    83605

    NCBI Accession

    NP_001025006

    UniProt

    Q9BSQ5

    Pathways

    Cell-Cell Junction Organization
You are here:
Chat with us!